AccuraGen Holding Limited
安可济控股有限公司
安可济控股有限公司
Biotech
Diagnostic & Medical Device
Menlo Park
CA
AccuraGen uniquely employs rolling-circle amplification to perform consensus-based concatemer error correction in liquid biopsy. The fundamental of our technology ensures a high conversion rate and minimizes the proliferations of errors. We optimized our assay to detect a breadth of genetic alterations with a sensitivity approaching the physical limit and a specificity as much as 100x better than benchmark.
安可济控股有限公司（AccuraGen Holdings Limited）始创于2013年8月，是一家致力并专精于基因高通量测序及其在癌症精准治疗中应用的高科技跨国公司。 安可济自主研发的Firefly™技术是一项划时代、革命性、超高精度、超高灵敏度高通量测序技术，已在美国及中国申请了专利保护。它能够准确检出外周血中的痕量循环肿瘤DNA（ctDNA）上百种肿瘤相关基因的体细胞突变，真正实现肿瘤的“液体活检”。
Liquid biopsy，DNA sequencing
